Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts disc ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.

Mirum Pharma's Ctexli has become the first FDA-approved therapy for cerebrotendinous xanthomatosis (CTX), an ultra-rare form ...

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...